Aims Mitral regurgitation (MR) confers independent risk in patients with acute myocardial infarction. We utilized data from the VALsartan In Acute myocardial iNfarcTion echo study to relate baseline MR to left ventricular (LV) size, shape, and function, and to assess the relationship between baseline MR and progression of MR and cardiovascular (CV) outcomes.
Introduction
Left ventricular (LV) remodelling after myocardial infarction (MI) can lead to apical and posterior displacement of the papillary muscles with resulting malcoaptation of the mitral leaflets and valvular insufficiency. [1] [2] [3] [4] Similar mechanisms appear to contribute to the functional mitral regurgitation (MR) seen often as a complication of systolic LV dysfunction (LVSD). 5, 6 In the acute and in the chronic phase after MI, MR has been shown to be associated with poor outcomes, 4, 7, 8 as is the case in patients with LV systolic dysfunction of other etiologies. 9, 10 The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial enrolled patients with acute myocardial infarction complicated by LVSD, heart failure (HF), or both. 11 We studied patients in the VALIANT echocardiographic substudy to determine the incidence and prognostic implications & The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org of MR following high-risk myocardial infarction, and to study the prognostic significance of progression of MR after infarction.
Methods

Study population
The VALIANT study enrolled 14 703 patients with LVSD [ejection fraction (EF) ,35% on echocardiography or ,40% on contrast angiography], clinical signs of HF or both, and randomized these patients to receive valsartan (target dose, 160 mg twice daily), captopril (target dose, 50 mg three times daily), or a combination of valsartan and captopril (target dose, 80 mg twice daily and 50 mg three times daily, respectively). 11 All patients gave their written informed consent, and the protocol was approved by the appropriate institutional review boards. The VALIANT Echo study was designed and powered prospectively to test the hypothesis that the angiotensin receptor blocker valsartan, either alone or combination with captopril, could attenuate progressive LV enlargement or improve LV function to a greater extent than captopril alone. 12 Patients were eligible if they had a myocardial infarction and evidence of LVSD (EF ,35% on echocardiography or ,40% on contrast angiography), HF or both, identical criteria to those for the main VALIANT study. All clinical sites participating in the main VALIANT study were invited to participate in the VALIANT echocardiographic substudy, and all patients enrolled in the VALIANT trial at participating sites were eligible for inclusion in the echo study.
Patients enrolled in the echocardiographic substudy (n ¼ 603) underwent two-dimensional echocardiography at a median of 5 (IQR 3-7) days after MI (prior to randomization). Assessment of MR by colourflow Doppler was possible in 496 patients, and not possible in 107 patients because of absence of colourflow Doppler or echocardiographic images of insufficient quality. Echocardiographic data were available in 419 patients at one month, and in 341 patients at 20 months.
Echocardiographic assessment
All two-dimensional echocardiograms were analysed by the core laboratory at the Brigham and Women's hospital. Echocardiograms from videotape were digitized and analyses were performed utilizing an offline analysis workstation. LV volumes and EFs were calculated in the usual fashion, as previously described. 12 Infarct location was assessed by determining the location of hypokinesis, akinesis, or dyskinesis.
The LV sphericity index was calculated as the ratio of LV volume (end diastolic and end systolic) and the volume of a sphere with a diameter equal to the LV (end diastolic and end systolic) long axis (sphericity index ¼ 6V/pL 3 ). 13 Mitral annular diameter was measured in four and two-chambers views at end diastole and end systole from three separate cardiac cycles, and annular areas were calculated by using an ellipsoid assumption (annular area ¼ d1 Â d2 Â p/4). 6, 14 Mitral annular contraction was defined as mitral end-diastolic annular area 2 mitral end-systolic annular area/mitral end-diastolic annular area.
MR was categorized mapping jet expansion in the left atrium (LA) in four and two-chamber views at end systole from three separate cardiac cycles. MR was considered mild when the regurgitant jet area occupied .5% and ,20% of the left atrial area, moderate when regurgitant jet area occupied .20% and ,40%, and severe when regurgitant jet area occupied .40% of the left atrial area. 15, 16 The grade of MR was increased by one degree (mild to moderate, moderate to severe) in the setting of an eccentric mitral regurgitant jet based on evidence of reduced colourflow jet areas due to loss of momentum in jets adjacent to chamber walls. 17 LA volume was assessed by the biplane area-length method from apical 4-and 2-chamber views at end systole from the frame preceding mitral valve opening. LA volume index was calculated as LA volume/body surface area (mL/m 2 ). Mitral flow velocity was assessed by transmitral pulsed wave Doppler study from the apical four chambers view with measurement of the E-and A-waves (in sinus rhythm) velocity, their ratio and the deceleration time of the E-wave.
Statistical methods
The intraobserver reproducibility of the MR measurement was assessed by the primary reader performing two sets of MR measurements in 15% of patients, randomly selected, in a blinded fashion. The Bland-Altman coefficient of repeatability was 1%. 18 We used linear-regression analysis to examine trends in clinical and echocardiographic characteristics across three MR groups, considering MR as an ordinal variable. The median follow-up time was 24.7 months. Clinical outcomes were adjudicated by an independent Clinical Endpoints Committee. Event rates were calculated using survival time data and expressed as events per 100 patient-years. We evaluated the effect of MR severity on outcomes of interest using Cox-proportional hazard regression models, adjusting for the most powerful covariate predictors of mortality identified from the overall VALIANT study. These were selected using both forward stepwise and backwards variable selection techniques applied to 70 baseline covariates, and validated with bootstrap resampling, 19 with the most important baseline demographic and echocardiographic baseline covariates included in the models [age, gender, heart rate, Killip class, percutaneous coronary intervention (PTCI) after MI, diabetes, history of HF, history of MI, renal insufficiency, EF, LV diastolic volume, left atrial volume]. A P-value ,0.05 was considered statistically significant.
Results
Baseline clinical characteristics
Baseline characteristics in the MR cohort and the remainder of the VALIANT cohort are shown in Table 1 . Patients in the MR cohort differed minimally from the overall VALIANT cohort, and were similar with respect to gender, BMI, Killip class, history of myocardial infarction, hypertension, diabetes, HF, smoking, infarct location, infarct type (Q-wave or non-Q-wave), and thrombolytic therapy. The MR cohort had slightly lower age, systolic and diastolic blood pressures, slightly higher rate of PTCI, and slightly higher use of ACE inhibitors and beta-blockers pre-randomization.
At baseline, MR was absent by colourflow Doppler echocardiography in 231 patients (46.6%), mild in 202 patients (40.7%), moderate in 49 (9.9%), and severe in 14 (2.8%). Patients with moderate and severe MR were grouped together because of small numbers in these groups (MR moderate-severe: n ¼ 63, 12.7%). No patient had evidence of significant structural valvular disease.
MR severity at baseline was associated with older age, female sex, history of MI, hypertension, diabetes, HF, and a non-Q-wave infarction ( Table 2) . Anterior infarction was less prevalent with increasing MR. Baseline medication use was similar in the three groups.
Echocardiographic characteristics
LV end-diastolic and end-systolic volumes were significantly increased, and EF significantly reduced, in patients with worse MR at baseline ( Table 3) . The LVs of patients with worse MR were significantly more spherical, and patients with worse MR had significant increases in diastolic and systolic mitral annular areas (MAAs), reduced annular contractility, and increased LA volume index. E-wave and E/A ratio were increased, and deceleration time was reduced in patients with worsening MR.
Relationship between baseline MR and clinical outcomes
In this cohort, 84 (16.9%) patients died [75 cardiovascular (CV)], 79 (15.9%) patients were hospitalized for HF, 134 (27%) patients either died or developed HF, and 50 (10.1%) patients had recurrent myocardial infarction. Any MR at baseline was associated with increased long-term mortality, CV death, hospitalization for HF, and death or HF hospitalization ( Table 4) . In a multivariable model adjusting for independent clinical and echocardiographic variables known to be predictive of outcome, the presence of any MR was found to be independently associated with long-term mortality [hazard ratio (HR) (95% CI), 1 (Figure 1 and 2 , Table 5 ). Baseline MR degree was associated with an increased number of total episodes of HF ( Figure 3 , P trend ,0.001).
Progression of MR and outcomes
MR jet to LA area ratio increased from 7.6 + 8.7% to 9.9 + 9.9% in 419 patients whose MR could be evaluated at 1 month after MI. In 341 patients with completed echocardiographic follow-up at 20 months, MR jet to LA area ratio increased from 6.7 + 7.8% at baseline to 9.1 + 9.5% at 20 months. Progression of MR from baseline to 1 month was associated with a significantly increased risk of death or HF hospitalization (adjusted HR per unit increase in MR jet/LA area ratio: 1.04, 95% CI 1.02-1.07, P ¼ 0.002; adjusted HR per increase in MR grade: 3.0, 95% CI, 1.8-4.9, P , 0.001; Table 6 ). In patients who survived and underwent a 20-month echocardiogram, MR progression was greater in those with one or more episodes of hospitalization for HF during that period than in patients who were event-free (MR jet/LA Area Ratio 7.8 + 11.3 vs. 1.5 + 7.7, P , 0.001). There were no differences in progression of MR at either one or 20-months based on treatment assignment.
Discussion
In patients with LVSD, HF, or both after acute MI, the degree of MR at baseline is associated with worse LV function, greater LV enlargement and chamber distortion, increased MAA and worse mitral annular contraction. The presence and degree of MR at baseline was significantly and independently associated with mortality and other adverse clinical outcomes. Moreover, worsening of MR between baseline and 1 month was associated with an increased risk of adverse outcomes, and patients whose MR progressed over the 20-month follow-up period had increased hospitalizations for HF during that period. MR has been shown to have independent prognostic value after acute and chronic MI. 3, 7, 20, 21 In the majority of patients with MR following MI, the MR is functional rather than due to inherent abnormalities of the mitral valve apparatus. In these individuals, the papillary muscles, chordae, and valve leaflets are normal, but distortion of ventricular geometry displaces the attachments of the mitral leaflets to the papillary muscles and annulus thereby restricting their ability to close effectively at the annular level, with resulting decrease in the LV-generated leaflet-closing force. 22, 23 In the present study, as previously shown, worse MR was more common in older people, 3, 4, 7, 20, 24, 25 women 4, 16, 26 , and in those with previous MI. 3 In contrast to other studies, we observed no clear relationship between severity of MR and infarct location. 27 Our data suggest that increased chamber sphericity may cause MR by lateral migration of the papillary muscles resulting in disadvantageous alignment of the papillary muscles apparatus relative to the mitral leaflets, 28 and are consistent with recent studies in which the most important determinant for the development of MR in patients with acute MI and in patients with LVSD was local LV remodelling. 6, 29 Our data demonstrate that a higher degree of MR is independently associated with an increased risk of mortality, CV mortality, and hospitalization for HF, even after adjusting for the most important known covariates. The early separation of the survival curves suggests that a higher degree of MR is a predictor of early outcome, adding incremental prognostic value over the other known predictors of outcome, including echocardiographic measures, such as EF and ventricular volume.
Moreover, we found that progression of MR, even within the first month after infarction, was associated with an increased risk of adverse outcomes. Worsening of MR during this early period may be a sensitive marker of early changes in ventricular geometry that might predispose to adverse outcome. While long-term worsening of MR was associated with increased HF, these data are inherently limited by survivor bias, as many patients with the worst degree of MR at baseline and 1 month died prior to the 20-month echocardiogram. Nevertheless, our data underscore the importance of detecting and quantifying and following the presence of MR after MI in patients with signs or symptoms of LVSD. Whether acute pharmacologic, surgical, or even percutaneous interventions might influence the progression of MR is not known. [30] [31] [32] [33] Some limitations of this study should be noted. We graded MR by colourflow Doppler, mapping regurgitant jet expansion within the LA, a method that may have resulted in misclassification of MR in some patients. More rigorous evaluation of regurgitant mitral lesions is possible using volumetric-based techniques such as proximal isovelocity surface area (PISA) method, but the necessary images for this technically more challenging and less widely used technique were not available in VALIANT, an international, multicenter clinical trial. Nevertheless, in a direct comparison of techniques in a single centre, the mitral jet area to LA ratio correlated well with effective regurgitant orifice area determined by the PISA method. 34 Finally, assessment of sphericity is limited by potential ventricular foreshortening.
In conclusion, we observed that even mild MR was associated with increased ventricular size, worse ventricular function, and alterations in ventricular geometry in patients with acute MI complicated by systolic dysfunction, HF, or both. Early post-infarct MR was an independent and important predictor of death or development of HF following MI, and progression of MR, even during the first month post-MI, was a potent predictor of subsequent outcome. Accurate assessment of MR and its progression following MI may help identify a particularly high-risk group who may benefit from aggressive adjunctive therapy.
